Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Serb
Deal Size : $412.0 million
Deal Type : Acquisition
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Details : Through the acquisition, SERB will leverage Y-mAbs pipeline, including its lead commercial oncology asset, Danyelza (naxitamab). It is being indicated for neuroblastoma.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : $412.0 million
August 05, 2025
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Serb
Deal Size : $412.0 million
Deal Type : Acquisition
Naxitamab + Irinotecan + Temozolomide Safety and Efficacy In Relapsed Neuroblastoma
Details : Naxitamab is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 18, 2025
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Nobelpharma
Deal Size : $33.0 million
Deal Type : Licensing Agreement
Y-mAbs And Nobelpharma Sign DANYELZA® Deal for Japanese Market
Details : The agreement aims for the development and commercialization in Japan of Danyelza (naxitamab) for high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : $2.0 million
November 04, 2024
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Nobelpharma
Deal Size : $33.0 million
Deal Type : Licensing Agreement
Details : Naxitamab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Y-mAbs DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil
Details : Danyelza® (naxitamab-gqgk) binds to the glycolipid GD2, indicated in combination with GMCSF, for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response to prior...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danyelza® (naxitamab-gqgk) binds to the glycolipid GD2, indicated in combination with GMCSF, for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response to prior...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : WEP Clinical
Deal Size : Undisclosed
Deal Type : Partnership
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
Details : Danyelza (naxitamab-gqgk) is a humanized, monoclonal antibody that binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and p...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 21, 2022
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : WEP Clinical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
Details : DANYELZA (naxitamab) is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered three times in a week in an outpatient setting and is repe...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
Details : DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor for treatment of pediatric patients 1 year of age and older and adult patients.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naxitamab,GM-CSF,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS® (omburtamab), which targets tumors that express B7-H3.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Naxitamab,GM-CSF,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable